drugset / Trial / NCT04591600
Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients
RandomizedParallel-groupSingle-blindTreatment
Summary
A randomized controlled trial on using Ivermectin and doxycycline to treat mild-moderate outpatients, severe, and critical inpatients of Coronavirus disease 19 (COVID-19) along with standard of care. Seventy Iraqi COVID-19 patients received Ivermectin and Doxycycline plus standard of care versus seventy Iraqi COVID-19 patients received standard of care only. .
Timeline
- Start
- 2020-07-01
- Primary completion
- 2020-09-30
- Completion
- 2020-10-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 100 mg | Oral |
| Subject | Ivermectin | Small molecule | 200 ug/kg | Oral |
| Background | Acetaminophen | Small molecule | 500 mg | — |
| Background | Azithromycin | Small molecule | 250 mg | — |
| Background | Cholecalciferol | Other / unclassified | 5000 iu | — |
| Background | Dexamethasone | Small molecule | 6 mg | — |
| Background | Methylprednisolone | Other / unclassified | 40 mg | — |
| Background | Vitamin C | Other / unclassified | 1000 mg | — |
| Background | Zinc Sulfate | Unknown | 75 mg | — |
| Background | Zinc Sulfate | Unknown | 125 mg | — |